Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conestat alfa open-label proof-of-concept study in pre-eclampsia
NL-OMON48732Phase 2Active, not recruiting
- Sponsor
- Pharming Group
- Start
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of c1-esterase inhibitor in preeclampsia, sponsored by Pharming Group. Primary endpoints: Incidence and severity of adverse events and Study drug discontinuation or study withdrawal. Started Jun 2019; status: active, not recruiting.
02
Drugs
c1-esterase inhibitor
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NL-OMON48732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48732.